Gilead To Stay ‘Proactive And Disciplined’ With Deals But M&A Not Urgent Priority

With 10 launches planned in the coming quarters, Gilead isn’t feeling the same acquisition urgency as its pharma peers—though the prospect of a takeover isn’t off the table.